Zevra insider sells 42,666 shares in planned trade

Q: What insider transaction did ZVRA report for Rahsaan Thompson on this Form 4?

Rahsaan Thompson reported a sale of 42,666 shares of Zevra Therapeutics common stock on 2026-08-14 in an open-market transaction, leaving him with 37,569 shares of direct ownership after the sale.

Q: At what price were the ZVRA shares sold by Rahsaan Thompson?

The reported transaction used a weighted average sale price of $11.1277 per share. The sale was executed in multiple trades, with prices ranging from $10.86 to $11.36, as disclosed in the transaction footnote.

Q: How many ZVRA shares does Rahsaan Thompson own after the reported sale?

After selling 42,666 shares, Rahsaan Thompson directly owns 37,569 shares of Zevra Therapeutics common stock. This remaining position is reported as direct ownership on the Form 4 following the 2026-08-14 transaction.

Q: Was the ZVRA insider sale by Rahsaan Thompson under a Rule 10b5-1 plan?

Yes. The filing states the transaction was made under a Rule 10b5-1(c) trading plan. A footnote reports the adoption date of the referenced 10b5-1(c) plan as 05-15-2026, and the plan status box is checked.

Q: How many total ZVRA shares were sold and what is the net effect reported?

The filing shows a net sale of 42,666 shares of Zevra Therapeutics common stock, all in this one reported transaction. The transaction summary reports netBuySellShares of -42,666, indicating a purely net-sell activity in this Form 4.

Zevra Therapeutics, Inc. (ZVRA) insider Rahsaan Thompson, Chief Legal & Compliance officer, reported selling 42,666 shares of common stock on 2026-08-14 in an open-market transaction under a Rule 10b5-1(c) trading plan.

Filing Impact

(Moderate)

Filing Sentiment

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Zevra Therapeutics, Inc. (ZVRA) insider Rahsaan Thompson, Chief Legal & Compliance officer, reported selling 42,666 shares of common stock on 2026-08-14 in an open-market transaction under a Rule 10b5-1(c) trading plan. The weighted average sale price was $11.1277 per share, and Thompson now holds 37,569 shares directly.

The sales were executed in multiple trades at prices between $10.86 and $11.36, with the weighted average reported. The referenced Rule 10b5-1(c) plan had an adoption date of 05-15-2026.

Insider Trade Summary 10b5-1

Net Seller: 42,666 shares

Net Sell 1 txn

Insider Thompson Rahsaan

Role Chief Legal & Compliance

Sold 42,666 shs ($475K)

Type	Security	Shares	Price	Value
Sale	Common Stock ^{F1, F2}	42,666	$11.1277	$475K

Holdings After Transaction: Common Stock — 37,569 shares (Direct)

Footnotes (2)

F1. Adoption date of referenced 10b5-1(c) plan is: 05-15-2026
F2. This transaction was executed in multiple trades at prices ranging from $10.86 to $11.36. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer or any security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

Key Figures

Shares sold: 42,666 shares Weighted average sale price: $11.1277 per share Price range of trades: $10.86 to $11.36 +3 more

6 metrics

Shares sold 42,666 shares Common Stock sold on 2026-08-14 in open-market transaction

Weighted average sale price $11.1277 per share Weighted average price for the 2026-08-14 sale transaction

Price range of trades $10.86 to $11.36 Range of execution prices across multiple trades in the sale

Shares owned after transaction 37,569 shares Directly owned Common Stock following the reported sale

Net buy/sell shares -42,666 shares NetBuySellShares reported in transaction summary for this Form 4

10b5-1(c) plan adoption date 05-15-2026 Adoption date of referenced Rule 10b5-1(c) trading plan

Key Terms

Rule 10b5-1(c) plan, weighted average sale price, Common Stock, open market or private transaction

4 terms

Rule 10b5-1(c) plan regulatory

"Adoption date of referenced 10b5-1(c) plan is: 05-15-2026"

weighted average sale price financial

"The price reported reflects the weighted average sale price."

Common Stock financial

"security_title: Common Stock for the reported transaction"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

open market or private transaction financial

"transaction_code_description: Sale in open market or private transaction"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ZVRA report for Rahsaan Thompson on this Form 4?

Rahsaan Thompson reported a sale of 42,666 shares of Zevra Therapeutics common stock on 2026-08-14 in an open-market transaction, leaving him with 37,569 shares of direct ownership after the sale.

At what price were the ZVRA shares sold by Rahsaan Thompson?

The reported transaction used a weighted average sale price of $11.1277 per share. The sale was executed in multiple trades, with prices ranging from $10.86 to $11.36, as disclosed in the transaction footnote.

How many ZVRA shares does Rahsaan Thompson own after the reported sale?

After selling 42,666 shares, Rahsaan Thompson directly owns 37,569 shares of Zevra Therapeutics common stock. This remaining position is reported as direct ownership on the Form 4 following the 2026-08-14 transaction.

Was the ZVRA insider sale by Rahsaan Thompson under a Rule 10b5-1 plan?

Yes. The filing states the transaction was made under a Rule 10b5-1(c) trading plan. A footnote reports the adoption date of the referenced 10b5-1(c) plan as 05-15-2026, and the plan status box is checked.

How many total ZVRA shares were sold and what is the net effect reported?

The filing shows a net sale of 42,666 shares of Zevra Therapeutics common stock, all in this one reported transaction. The transaction summary reports netBuySellShares of -42,666, indicating a purely net-sell activity in this Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 08/17/2026 - 04:33 PM Accepted by SEC EDGAR 08/17/2026 - 04:32 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Thompson Rahsaan

(Last)

(First)

(Middle)

C/O ZEVRA THERAPEUTICS, INC.

101 FEDERAL STREET

(Street)

BOSTON

MASSACHUSETTS

02110

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ZEVRA THERAPEUTICS, INC. [ ZVRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Legal & Compliance

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/14/2026		S⁽¹⁾		42,666	D	$11.1277⁽²⁾	37,569	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Adoption date of referenced 10b5-1(c) plan is: 05-15-2026

2. This transaction was executed in multiple trades at prices ranging from $10.86 to $11.36. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer or any security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

	/s/ Timothy J. Sangiovanni, Attorney-in-Fact for Rahsaan W. Thompson	08/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR